Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Michael Batey.

Newcastle AuthorsTitleYearFull text
Dr Britta Vormoor
Henrike Knizia
Michael Batey
Dr Ian Wilson
Dr Petra Dildey
et al.
Development of a Preclinical Orthotopic Xenograft Model of Ewing Sarcoma and Other Human Malignant Bone Disease Using Advanced In Vivo Imaging2014
Michael Batey
Dr Frida Ponthan
Dr Helen Blair
Professor Olaf Heidenreich
The development and evaluation of a series of novel in vivo imaging models of AML for the assessment of drug efficacy2014
Michael Batey
Dr Yan Zhao
Suzanne Kyle
Professor Herbie Newell
Professor Nicola Curtin
et al.
Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer2013
Michael Batey
Dr Frida Ponthan
Professor Olaf Heidenreich
The use of a novel in vivo orthotopic imaging model of AML for assessment of drug efficacy2013
Dr Joanne Martin
Michael Batey
Dr Yan Zhao
Dr Celine Cano
Dr Michele Tavecchio
et al.
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K2012
Michael Batey
Dr Yan Zhao
Dr Helen Maitland
Professor Hing Leung
Emeritus Professor Andy Hall
et al.
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma2011
Michael Batey
Professor Julie Irving
Professor Herbie Newell
Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models2011
Patricia Garrido Castro
Dr Simon Bomken
Elda Latif
Michael Batey
Hesta McNeill
et al.
ANGIOPOIETIN1 a Novel Factor Implicated In MLL Rearranged Acute Lymphoblastic Leukemia and Regulated In a Fusion Gene Dependent Manner2010
Elda Latif
Michael Batey
Hesta McNeill
Professor Hermann Josef Vormoor
Professor Olaf Heidenreich
et al.
ANGIOPOIETIN1-a Novel Factor Implicated In MLL-Rearranged Acute Lymphoblastic Leukemia and Regulated In a Fusion Gene-Dependent Manner2010
Henrike Knizia
Michael Batey
Gilberto de Almeida
Dr Ross Maxwell
Dr Petra Dildey
et al.
Development of an orthotopic model for human malignant bone diseases in immunocompromised NOD.Cg-PrkdcscidIl2rgtmlwjl/szj (NSG) mice2010
Michael Batey
Professor Herbie Newell
Professor Nicola Curtin
Chemosensitisation of cancer cells by KU-0060648, a potent and selective inhibitor of DNA-PK [abstract]2008
Michael Batey
Dr Amy Peasland
Professor Julie Irving
Professor Herbie Newell
Development of inhibitors of the fibroblast growth factor receptor (FGFR) kinase using a fragment based approach2008
Michael Batey
Dr Helen Maitland
Professor Hing Leung
Emeritus Professor Andy Hall
Professor Graham Jackson
et al.
In vitro activity of the multi targeted receptor tyrosine kinase inhibitor sunitinib against multiple myeloma cell lines is not predictive of in vivo xenograft response2008
Michael Batey
Dr Laurent Rigoreau
Professor Roger Griffin
Professor Herbie Newell
Professor Nicola Curtin
et al.
Potent in vitro and in vivo radiosensitisation by the selective DNA-dependent protein kinase inhibitor KU-0060648 [abstract]2008
Dr Patricia Turner
Mike Cole
Michael Batey
Sandra Beare
Professor Alan Boddy
et al.
Reduced folate carrier single nucleotide polymorphism associated with methotrexate clearance in breast cancer patients2008
Huw Thomas
Dr Christopher Calabrese
Michael Batey
Suzanne Kyle
Professor Herbie Newell
et al.
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial2007
Dr Yan Zhao
Huw Thomas
Michael Batey
Dr Ian Cowell
Professor Roger Griffin
et al.
Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU74412006
Dr Christopher Calabrese
Michael Batey
Professor Alan Calvert
Emeritus Professor Barbara Durkacz
Suzanne Kyle
et al.
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG143612004
Dr Christopher Calabrese
Michael Batey
Huw Thomas
Emeritus Professor Barbara Durkacz
Lan Wang
et al.
Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies2003
Michael Batey
Dr Ashraf Azzabi
Professor Herbie Newell
Professor Alan Calvert
Professor Alan Boddy
et al.
Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) 2002
Michael Batey
Dr Ashraf Azzabi
Professor Herbie Newell
Professor Alan Calvert
Professor Alan Boddy
et al.
Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)2002
Professor Nicola Curtin
Dr Stephen Barton
Michael Batey
Dr Christopher Calabrese
Professor Alan Calvert
et al.
Anti-cancer chemosensitization in vitro and in vivo by a novel potent poly(ADP-ribose) polymerase (PARP1) inhibitor, TBI-361.2001
Dr Christopher Calabrese
Professor Nicola Curtin
Michael Batey
Huw Thomas
Suzanne Kyle
et al.
Design and evaluation of novel potent inhibitors of poly (ADP-ribose) polymerase2000
Michael Batey
Kevin Fishwick
Dr Ashraf Azzabi
Professor Herbie Newell
Professor Alan Calvert
et al.
Population pharmacokinetics of CMF in the adjuvant treatment of breast cancer1999
Dr Christopher Calabrese
Huw Thomas
Michael Batey
Professor Nicola Curtin
Professor Roger Griffin
et al.
Preclinical pharmacology of novel substituted benzimidazoles - potent inhibitors of poly (ADP-ribose) polymerase1999